Engineered immune cells take on Hard-to-Treat sarcoma
NCT ID NCT00902044
First seen Jan 27, 2026 · Last updated May 15, 2026 · Updated 18 times
Summary
This study tests a new treatment for people with advanced sarcoma, a type of cancer that has not responded to standard therapies. Researchers take a patient's own immune cells (T cells) and add a new gene to help them recognize and attack cancer cells that have a protein called HER2. Before receiving the modified cells, some patients get chemotherapy to help the cells work better. The main goals are to find a safe dose and see if the treatment can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Houston Methodist Hospital
Houston, Texas, 77030, United States
-
Texas Children's Hospital
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.